AccuPulse Medical Technology, a Jiangsu, China-based-announced that it raised more than $10 million in a Series A funding round.
Shenzhen Qianhai Capital led the funding round, with Shanghai Biomedical Industry Equity Investment Fund and Yuanbio Ventures jointly investing.
AccuPulse funding round will finance the clinical trial of its PFA system and new product development
Company Name: AccuPulse Medical Inc.
Round: Series A
Funding Month: May 2022
Lead Investors: Shenzhen Qianhai Capital led the funding
Additional Investors: Shanghai Biomedical Industry Equity Investment Fund and Yuanbio Ventures jointly investing.
Company Website: http://www.accupulse.com/h-col-101.html
Software Category: electrophysiological platform
About the Company: Founded in November 2020, AccuPulse is dedicated to become a globally leading innovator in cardiac electrophysiology industry. AccuPulse develops electrophysiology technology designed as a one-stop solution to treat cardiac arrhythmias, especially atrial fibrillation. Its product line includes an artificial intelligence (AI)-powered 3D mapping system, diagnostic and pulsed field ablation (PFA) catheters, a transseptal kit and an intracardiac ultrasound catheter to meet the requirements for electrophysiology surgery with zero radiation.The core team members come from companies such as J&J, GE, Acutus Medical and Abbott with in-depth experience in R&D, registration and commercialization of cardiac electrophysiological medical devices. The company has built R&D centers in both China and the United States, and the company is backed by top scientists, physicians and famous venture capital firms.